• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Danimer Scientific Announces Third Quarter 2023 Results

    11/14/23 4:01:00 PM ET
    $DNMR
    Major Chemicals
    Industrials
    Get the next $DNMR alert in real time by email

    -- PHA-Based Product Revenue Grows 58% vs. Prior Year --

    -- Bid Awards Issued to Danimer Converter Partners for Nodax-Based Cutlery Require Approximately 20 million pounds of resin annually --

    -- Reduced Guidance Reflects Changes in Customer Launches and Timing of First Shipments --

    Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of highly engineered biodegradable materials, today announced financial results for its third quarter, ended September 30, 2023.

    Stephen E. Croskrey, Chairman and Chief Executive Officer of Danimer, commented, "We are excited to announce that new business awards associated with a large Quick Service Restaurant program for Nodax-based biodegradable cutlery have been issued to several of our converter partners. Total demand for our product is expected to be approximately 20 million pounds per year at full run-rate, with first shipments expected to begin in the second half of next year. With these cutlery awards, we've now opened another significant product category for our PHA-based resins, which further validates our product in the marketplace and will continue to drive volume across our manufacturing assets."

    Mr. Croskrey continued, "While our sales expectations for the second half of 2023 were adversely impacted by timing delays among several anticipated commercial programs, we believe our work with our commercial partners on these programs is nearly complete and look forward to products launching throughout 2024. We're pleased to be working with several major brands and share in their commitment to ensuring that each launch transitioning products and packaging from traditional petroleum-based plastics to a more sustainable material is both seamless and an unqualified success. While the time and resources to complete these final steps are proving to be more extensive than we had previously anticipated, particularly with respect to certain novel end-use applications, we are more confident than ever that these launches will enable enduring success. Our materials enable brands to differentiate competitively, extend their environmental leadership roles, and enhance their reputations for sustainability."

    Mr. Croskrey concluded, "Each product launch is generating strong interest from and opportunity to engage with new commercial partners seeking long-term solutions to plastic waste across multiple product categories and industries. While we are disappointed our near-term financial expectations were not met, we view this as a temporary delay and retain our conviction that we are on the right path toward filling our existing capacity and continuing to make progress on our planned footprint expansion strategy."

    Third Quarter 2023 Financial Highlights:

    • Revenues in the third quarter grew to $10.9 million compared to $10.4 million in the year-ago quarter. Strong growth in sales of PHA-based products, which represented 78% of total revenue this quarter compared to 51% in the third quarter of last year, offset expected year-over-year declines in other areas. PLA-based resin sales decreased by $1.8 million relative to last year as a result of business interrupted by the Ukraine conflict. Service revenue in the third quarter was $0.5 million as compared to $1.3 million last year, the continuing result of the successful completion of development work for certain customers now progressing to commercialization.
    • Gross profit in the third quarter was $(7.7) million compared to $(4.1) million in the third quarter of 2022. Adjusted gross profit was $(2.6) million compared to $(1.5) million in the third quarter of last year. The reduction in adjusted gross profit primarily reflects increased fixed production costs associated with greater capacity.
    • Third quarter net loss was $(40.2) million this year compared to a net loss of $(94.9) million last year, primarily reflecting a non-recurring, non-cash goodwill impairment charge of $62.7 million in the prior year.
    • Adjusted EBITDA was $(9.3) million in the third quarter of 2023 compared to $(12.9) million in the third quarter of 2022. The ongoing improvement in adjusted EBITDA primarily reflects the Company's comprehensive program of expense control measures.

    Capital Structure

    At September 30, 2023, the Company reported a total debt balance of $379.9 million, including approximately $45.7 million dollars of low-interest New Markets Tax Credit loans that the Company expects will be forgiven between 2026 and 2029. At September 30, 2023, cash and cash equivalents and restricted cash, which is primarily held to satisfy future interest payments, totaled $91.9 million.

    Outlook

    The Company's previous full-year adjusted EBITDA guidance range was based on expected strong second half revenue growth through new customer product launches and associated first shipments that did not materialize as planned. Accordingly, the Company has modified its full-year 2023 adjusted EBITDA guidance to a range of $(40) million to $(37) million and will look forward to finalizing a number of expected product launches in 2024. Separately, the Company now anticipates full-year capital expenditures in the range of $27 million to $29 million, which is a revision toward the more favorable end of its wider previous range.

    Webcast & Conference Call

    A webcast and conference call will be held today, November 14, at 4:30 p.m. Eastern Time to review the Company's third quarter results, discuss recent events and conduct a question-and-answer session. The live webcast of the conference call can be accessed on the Investor Relations section of the Company's website at https://ir.danimerscientific.com.

    For those unable to access the webcast, the conference call will be accessible domestically or internationally, by dialing 1-888-886-7786 or 1-416-764-8658, respectively. Upon dialing in, please request to join the Danimer Scientific Third Quarter 2023 Earnings Conference Call. The archived webcast will be available for replay on the Company's website after the call.

    About Danimer Scientific

    Danimer is a pioneer in creating more sustainable, more natural ways to make plastic products. For more than a decade, its renewable and sustainable biopolymers have helped create plastic products that are biodegradable and compostable and return to nature instead of polluting our lands and waters. Danimer's technology can be found in a vast array of plastic end products that people use every day. Applications for its biopolymers include additives, aqueous coatings, extrusion coating, fibers, filaments, films and injection-molded articles, among others. Danimer holds more than 480 granted patents and pending patent applications in more than 20 countries for a range of manufacturing processes and biopolymer formulations. For more information, please visit https://danimerscientific.com.

    Forward-Looking Statements

    Please note that this press release may use words such as "appears," "anticipates," "believes", "plans," "expects," "intends," "future", and similar expressions which constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding our expectations for full year 2023 capital expenditures, Adjusted EBITDA and cash balances. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve a number of risks and uncertainties. We caution that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statements. Potential risks and uncertainties that could cause the actual results of operations or financial condition of the Company to differ materially from those expressed or implied by forward-looking statements in this release include, but are not limited to, the overall level of consumer demand on our products; general economic conditions and other factors affecting consumer confidence, preferences, and behavior; disruption and volatility in the global currency, capital, and credit markets; the financial strength of the Company's customers; the Company's ability to implement its business strategy, including, but not limited to, its ability to expand its production facilities and plants to meet customer demand for its products and the timing thereof; risks relating to the uncertainty of the projected financial information with respect to the Company; the ability of the Company to execute and integrate acquisitions; changes in governmental regulation, legislation or public opinion relating to our products; the Company's exposure to product liability or product warranty claims and other loss contingencies; disruptions and other impacts to the Company's business, as a result of the COVID-19 global pandemic and government actions and restrictive measures implemented in response; stability of the Company's manufacturing facilities and suppliers, as well as consumer demand for our products, in light of disease epidemics and health-related concerns such as the COVID-19 global pandemic; the impact on our business, operations and financial results from the ongoing conflict in Ukraine; the impact that global climate change trends may have on the Company and its suppliers and customers; the Company's ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, our information systems; the ability of our information technology systems or information security systems to operate effectively, including as a result of security breaches, viruses, hackers, malware, natural disasters, vendor business interruptions or other causes; our ability to properly maintain, protect, repair or upgrade our information technology systems or information security systems, or problems with our transitioning to upgraded or replacement systems; the impact of adverse publicity about the Company and/or its brands, including without limitation, through social media or in connection with brand damaging events and/or public perception; fluctuations in the price, availability and quality of raw materials and contracted products as well as foreign currency fluctuations; our ability to utilize potential net operating loss carryforwards; and changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks. More information on potential factors that could affect the Company's financial results is included from time to time in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, and speak only as of the date hereof. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release.

    Danimer Scientific, Inc.

    Condensed Consolidated Balance Sheets

     

     

    September 30,

     

    December 31,

    (in thousands, except share and per share data)

     

    2023

     

    2022

    Assets:

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    77,393

     

     

    $

    62,792

     

    Accounts receivable, net

     

     

    12,422

     

     

     

    17,989

     

    Other receivables, net

     

     

    715

     

     

     

    1,635

     

    Inventories, net

     

     

    26,685

     

     

     

    32,743

     

    Prepaid expenses and other current assets

     

     

    4,754

     

     

     

    5,225

     

    Contract assets, net

     

     

    5,103

     

     

     

    4,687

     

    Total current assets

     

     

    127,072

     

     

     

    125,071

     

     

     

     

     

     

     

     

    Property, plant and equipment, net

     

     

    449,824

     

     

     

    453,949

     

    Intangible assets, net

     

     

    78,660

     

     

     

    80,941

     

    Right-of-use assets

     

     

    19,157

     

     

     

    19,028

     

    Leverage loans receivable

     

     

    31,446

     

     

     

    31,446

     

    Restricted cash

     

     

    14,461

     

     

     

    1,609

     

    Other assets

     

     

    346

     

     

     

    226

     

    Total assets

     

    $

    720,966

     

     

    $

    712,270

     

     

     

     

     

     

     

     

    Liabilities and Stockholders' Equity:

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    3,909

     

     

    $

    14,977

     

    Accrued liabilities

     

     

    5,899

     

     

     

    5,001

     

    Deferred revenue

     

     

    438

     

     

     

    -

     

    Current portion of lease liability

     

     

    3,337

     

     

     

    3,337

     

    Current portion of long-term debt, net

     

     

    1,184

     

     

     

    1,972

     

    Total current liabilities

     

     

    14,767

     

     

     

    25,287

     

     

     

     

     

     

     

     

    Private warrants liability

     

     

    113

     

     

     

    212

     

    Long-term lease liability, net

     

     

    21,965

     

     

     

    22,114

     

    Long-term debt, net

     

     

    378,687

     

     

     

    286,398

     

    Deferred income taxes

     

     

    -

     

     

     

    200

     

    Other long-term liabilities

     

     

    1,153

     

     

     

    447

     

    Total liabilities

     

    $

    416,685

     

     

    $

    334,658

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

    Common stock, $0.0001 par value; 200,000,000 shares authorized: 102,035,267 and 101,804,454 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively

     

    $

    10

     

     

    $

    10

     

    Additional paid-in capital

     

     

    718,958

     

     

     

    676,250

     

    Accumulated deficit

     

     

    (414,687

    )

     

     

    (298,648

    )

    Total stockholders' equity

     

     

    304,281

     

     

     

    377,612

     

    Total liabilities and stockholders' equity

     

    $

    720,966

     

     

    $

    712,270

     

    Danimer Scientific, Inc.

    Condensed Consolidated Statements of Operations

     

     

    Three Months Ended September 30,

     

    Nine Months Ended September 30,

    (in thousands, except share and per share data)

     

    2023

     

    2022

     

    2023

     

    2022

    Revenue:

     

     

     

     

     

     

     

     

     

     

     

     

    Products

     

    $

    10,454

     

     

    $

    9,099

     

     

    $

    33,724

     

     

    $

    33,890

     

    Services

     

     

    494

     

     

     

    1,349

     

     

     

    2,015

     

     

     

    4,004

     

    Total revenue

     

     

    10,948

     

     

     

    10,448

     

     

     

    35,739

     

     

     

    37,894

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Costs and expenses:

     

     

     

     

     

     

     

     

     

     

     

     

    Cost of revenue

     

     

    18,685

     

     

     

    14,503

     

     

     

    56,327

     

     

     

    45,606

     

    Selling, general and administrative

     

     

    16,555

     

     

     

    19,413

     

     

     

    52,098

     

     

     

    62,042

     

    Research and development

     

     

    6,883

     

     

     

    7,947

     

     

     

    21,667

     

     

     

    24,469

     

    Loss on sale of assets

     

     

    64

     

     

     

    -

     

     

     

    234

     

     

     

    1

     

    Impairment of long-lived assets

     

     

    -

     

     

     

    63,491

     

     

     

    -

     

     

     

    63,491

     

    Total costs and expenses

     

     

    42,187

     

     

     

    105,354

     

     

     

    130,326

     

     

     

    195,609

     

    Loss from operations

     

     

    (31,239

    )

     

     

    (94,906

    )

     

     

    (94,587

    )

     

     

    (157,715

    )

    Nonoperating income (expense):

     

     

     

     

     

     

     

     

     

     

     

     

    Gain on remeasurement of private warrants

     

     

    132

     

     

     

    1,607

     

     

     

    99

     

     

     

    8,614

     

    Interest, net

     

     

    (8,584

    )

     

     

    (553

    )

     

     

    (21,132

    )

     

     

    (2,197

    )

    Loss on loan extinguishment

     

     

    -

     

     

     

    (1,500

    )

     

     

    (102

    )

     

     

    (1,500

    )

    Other, net

     

     

    -

     

     

     

    240

     

     

     

    -

     

     

     

    324

     

    Total nonoperating income (expense):

     

     

    (8,452

    )

     

     

    (206

    )

     

     

    (21,135

    )

     

     

    5,241

     

    Loss before income taxes

     

     

    (39,691

    )

     

     

    (95,112

    )

     

     

    (115,722

    )

     

     

    (152,474

    )

    Income taxes

     

     

    (468

    )

     

     

    236

     

     

     

    (317

    )

     

     

    767

     

    Net loss

     

    $

    (40,159

    )

     

    $

    (94,876

    )

     

    $

    (116,039

    )

     

    $

    (151,707

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted net loss per share

     

    $

    (0.39

    )

     

    $

    (0.94

    )

     

    $

    (1.14

    )

     

    $

    (1.50

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average number of shares used to compute:

     

     

     

     

     

     

     

     

     

     

     

     

    Basic and diluted net loss per share

     

     

    102,025,684

     

     

     

    101,199,195

     

     

     

    101,953,827

     

     

     

    100,993,068

     

    Danimer Scientific, Inc.

    Condensed Consolidated Statements of Cash Flows

     

     

    Nine Months Ended

     

     

    September 30,

    (in thousands)

     

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

     

     

     

    Net loss

     

    $

    (116,039

    )

     

    $

    (151,707

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

     

     

     

    Stock-based compensation

     

     

    42,227

     

     

     

    42,398

     

    Depreciation and amortization

     

     

    22,005

     

     

     

    13,172

     

    Amortization of debt issuance costs

     

     

    6,209

     

     

     

    1,601

     

    Accounts receivable reserves

     

     

    (1,462

    )

     

     

    1,205

     

    Inventory reserves

     

     

    540

     

     

     

    609

     

    Amortization of right-of-use assets and lease liability

     

     

    (278

    )

     

     

    (270

    )

    Loss on disposal of assets

     

     

    234

     

     

     

    1

     

    Deferred income taxes

     

     

    (199

    )

     

     

    (767

    )

    Loss on extinguishment of debt

     

     

    102

     

     

     

    1,500

     

    Gain on remeasurement of private warrants

     

     

    (99

    )

     

     

    (8,614

    )

    Contract asset reserve

     

     

    -

     

     

     

    1,215

     

    Impairment of long-lived assets

     

     

    -

     

     

     

    63,491

     

    Other

     

     

    941

     

     

     

    43

     

    Changes in operating assets and liabilities

     

     

     

     

     

     

    Accounts receivable

     

     

    7,029

     

     

     

    (1,747

    )

    Other receivables

     

     

    555

     

     

     

    2,724

     

    Inventories, net

     

     

    5,475

     

     

     

    (14,271

    )

    Prepaid expenses and other current assets

     

     

    1,816

     

     

     

    1,749

     

    Contract assets

     

     

    (1,244

    )

     

     

    (2,019

    )

    Other assets

     

     

    (119

    )

     

     

    (5

    )

    Accounts payable

     

     

    (2,061

    )

     

     

    (4,642

    )

    Accrued liabilities

     

     

    1,893

     

     

     

    (5,037

    )

    Other long-term liabilities

     

     

    706

     

     

     

    3

     

    Unearned revenue and contract liabilities

     

     

    438

     

     

     

    1,786

     

    Net cash used in operating activities

     

     

    (31,331

    )

     

     

    (57,582

    )

    Cash flows from investing activities:

     

     

     

     

     

     

    Purchases of property, plant and equipment and intangible assets

     

     

    (25,722

    )

     

     

    (133,632

    )

    Proceeds from sales of property, plant and equipment

     

     

    18

     

     

     

    55

     

    Investment in leverage loan receivable related to NMTC financing

     

     

    -

     

     

     

    (18,037

    )

    Acquisition of Novomer, net of cash acquired

     

     

    -

     

     

     

    (14

    )

    Net cash used in investing activities

     

     

    (25,704

    )

     

     

    (151,628

    )

    Cash flows from financing activities:

     

     

     

     

     

     

    Proceeds from long-term debt

     

     

    130,000

     

     

     

    24,700

     

    Cash paid for debt issuance costs

     

     

    (33,296

    )

     

     

    (1,547

    )

    Principal payments on long-term debt

     

     

    (12,437

    )

     

     

    (886

    )

    Proceeds from employee stock purchase plan

     

     

    282

     

     

     

    526

     

    Employee taxes related to stock-based compensation

     

     

    (61

    )

     

     

    -

     

    Proceeds from exercise of stock options

     

     

    -

     

     

     

    215

     

    Proceeds from issuance of common stock, net of issuance costs

     

     

    -

     

     

     

    79

     

    Cost related to warrants

     

     

    -

     

     

     

    (55

    )

    Net cash provided by financing activities

     

     

    84,488

     

     

     

    23,032

     

    Net increase (decrease) in cash and cash equivalents and restricted cash

     

     

    27,453

     

     

     

    (186,178

    )

    Cash and cash equivalents and restricted cash-beginning of period

     

     

    64,401

     

     

     

    286,968

     

    Cash and cash equivalents and restricted cash-end of period

     

    $

    91,854

     

     

    $

    100,790

     

    Non-GAAP Financial Measures

    This press release includes the non-GAAP financial measures "Adjusted EBITDA", "Adjusted gross profit" and "Adjusted gross margin". Danimer management views these metrics as a useful way to look at the performance of its operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions.

    Adjusted EBITDA is defined as net income or loss plus net interest expense, income taxes, depreciation and amortization, as adjusted to add back certain charges or gains that Danimer may record each period such as remeasurement of private warrants, stock-based compensation expense, as well as non-recurring charges such as (i) asset disposal gains or losses as well as other significant gains or losses such as debt extinguishments and impairment of goodwill; (ii) legal settlements; or (iii) other discrete non-recurring items. Danimer believes these items are not considered an indicator of ongoing performance. Adjusted EBITDA is not a measure of performance defined in accordance with GAAP. The measure is used as a supplement to GAAP results in evaluating certain aspects of Danimer's business, as described below.

    Adjusted gross profit is defined as gross profit plus depreciation, stock-based compensation and nonrecurring items.

    Adjusted gross margin is defined as adjusted gross profit divided by total revenue.

    Danimer believes that each of Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin is useful to investors in evaluating the Company's performance because each measure considers the performance of the Company's operations, excluding decisions made with respect to capital investment, financing and other non-recurring charges as outlined in the preceding paragraph. Danimer believes these non-GAAP metrics offer additional financial information that, when coupled with the GAAP results and the reconciliation to GAAP results, provides a more complete understanding of its results of operations and the factors and trends affecting its business.

    Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin should not be considered as an alternative to net income or loss as an indicator of its performance or as alternatives to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. Although Danimer believes that Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin may enhance an evaluation of its operating performance based on recent revenue generation and product/overhead cost control because it excludes the impact of prior decisions made about capital investment, financing and other expenses, (i) other companies in Danimer's industry may define Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin differently than Danimer does and, as a result, they may not be comparable to similarly titled measures used by other companies in its industry, and (ii) Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin exclude certain financial information that some may consider important in evaluating Danimer's performance.

    Danimer compensates for these limitations by providing disclosure of the differences between Adjusted EBITDA, Adjusted gross profit and Adjusted gross margin and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of Danimer's operating results. Because GAAP financial measures on a forward-looking basis are not accessible, and reconciling information is not available without unreasonable effort, reconciliations to GAAP financial measures are not provided for forward-looking non-GAAP measures. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

    Danimer Scientific, Inc.

    Reconciliation of Adjusted EBITDA to Net Income (Loss) (Unaudited)

     

     

    Three Months Ended September 30,

     

     

    2023

     

    2022

    (in thousands)

     

     

     

     

     

     

    Net loss

     

    $

    (40,159

    )

     

    $

    (94,876

    )

    Stock-based compensation

     

     

    14,324

     

     

     

    14,305

     

    Interest, net

     

     

    8,584

     

     

     

    553

     

    Depreciation and amortization

     

     

    7,253

     

     

     

    4,585

     

    Income taxes

     

     

    468

     

     

     

    (236

    )

    Gain on remeasurement of private warrants

     

     

    (132

    )

     

     

    (1,607

    )

    Strategic reorganization and related

     

     

    382

     

     

     

    -

     

    Litigation and other legal related

     

     

    28

     

     

     

    375

     

    Loss on extinguishment of debt

     

     

    -

     

     

     

    1,500

     

    Impairment of goodwill

     

     

    -

     

     

     

    62,663

     

    Public company transition

     

     

    -

     

     

     

    35

     

    Other, net

     

     

    -

     

     

     

    (240

    )

    Adjusted EBITDA

     

    $

    (9,252

    )

     

    $

    (12,943

    )

    Reconciliation of Adjusted Gross Profit (Loss) to Gross Profit (Loss) (Unaudited)

     

     

    Three Months Ended September 30,

     

     

    2023

     

    2022

    (in thousands)

     

     

     

     

     

     

    Total revenue

     

    $

    10,948

     

     

    $

    10,448

     

    Cost of revenue

     

     

    18,685

     

     

     

    14,503

     

    Gross loss

     

     

    (7,737

    )

     

     

    (4,055

    )

    Depreciation

     

     

    5,086

     

     

     

    2,571

     

    Stock-based compensation

     

     

    2

     

     

     

    22

     

    Adjusted gross loss

     

    $

    (2,649

    )

     

    $

    (1,462

    )

     

     

     

     

     

     

     

    Adjusted gross margin

     

     

    -24.2

    %

     

     

    -14.0

    %

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231114713771/en/

    Get the next $DNMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNMR

    DatePrice TargetRatingAnalyst
    11/21/2024$40.00 → $5.50Hold
    TD Cowen
    11/20/2024$40.00 → $4.00Neutral → Underweight
    Piper Sandler
    8/13/2024$2.00 → $1.00Buy → Hold
    TD Cowen
    5/22/2024$1.30 → $0.80Buy → Hold
    Jefferies
    4/9/2024$3.50 → $1.25Overweight → Neutral
    Piper Sandler
    10/12/2022$4.50Overweight
    Piper Sandler
    9/23/2021$21.00Outperform
    Cowen
    More analyst ratings

    $DNMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Hajost Michael A converted options into 859 shares and covered exercise/tax liability with 301 shares, increasing direct ownership by 31% to 2,334 units (SEC Form 4)

    4 - Danimer Scientific, Inc. (0001779020) (Issuer)

    2/10/25 4:30:05 PM ET
    $DNMR
    Major Chemicals
    Industrials

    Director Moody David Jesse converted options into 646 shares (SEC Form 4)

    4 - Danimer Scientific, Inc. (0001779020) (Issuer)

    1/21/25 4:30:10 PM ET
    $DNMR
    Major Chemicals
    Industrials

    SEC Form 4 filed by Director Croskrey Stephen

    4 - Danimer Scientific, Inc. (0001779020) (Issuer)

    1/3/25 4:05:07 PM ET
    $DNMR
    Major Chemicals
    Industrials

    $DNMR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace

    –Dividend warrants continue to trade on OTCQX marketplace under "DNMRW"– Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange ("NYSE") suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the Company did not meet the continued listing standard that requires listed companies to maintain a

    12/31/24 8:00:00 AM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific Takes Action to Strengthen Capital Structure

    Announces Issuance of $11,250,000 Super Senior Secured Promissory Note Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that the Company issued a super senior secured promissory note (the "Secured Loan") in an aggregate principal amount of $11,250,000 to certain lenders under its existing term loan financing agreement, as well as certain additional lenders. The Secured Loan provides for $11,250,000 gross proceeds, less fees and expenses. The Secured Loan has a two-year maturity and accrues interest at 15.0% per annum, which interest is payab

    12/17/24 4:15:00 PM ET
    $DNMR
    Major Chemicals
    Industrials

    TerraNova Capital Equities announces three transactions totaling $45 Million

    NEW YORK, Nov. 20, 2024 /PRNewswire/ -- TerraNova Capital Equities, inc. (TerraNova), a leading financial advisory firm, is pleased to announce that its Structure Finance Group acted as sole advisor on three recent transactions: TerraNova Structured Finance Group acted as the sole advisor to Danimer Scientific, Inc. (NYSE:DNMR) on a $20 Million revolving credit facility. TerraNova is pleased to announce its role as the exclusive advisor to Danimer Scientific in securing a strategic ABL agreement with Mountain Ridge Capital.  This $20 million facility, collateralized by the Com

    11/20/24 10:30:00 AM ET
    $DNMR
    $INUV
    Major Chemicals
    Industrials
    Advertising
    Consumer Discretionary

    $DNMR
    SEC Filings

    View All

    Danimer Scientific Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Danimer Scientific, Inc. (0001779020) (Filer)

    3/18/25 5:00:42 PM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Danimer Scientific, Inc. (0001779020) (Filer)

    2/28/25 5:00:09 PM ET
    $DNMR
    Major Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Danimer Scientific Inc.

    SCHEDULE 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

    2/14/25 5:41:32 PM ET
    $DNMR
    Major Chemicals
    Industrials

    $DNMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hendrix Richard J bought $93,395 worth of shares (100,000 units at $0.93) (SEC Form 4)

    4 - Danimer Scientific, Inc. (0001779020) (Issuer)

    11/28/23 5:35:32 PM ET
    $DNMR
    Major Chemicals
    Industrials

    $DNMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on Danimer Scientific with a new price target

    TD Cowen reiterated coverage of Danimer Scientific with a rating of Hold and set a new price target of $5.50 from $40.00 previously

    11/21/24 8:09:13 AM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Danimer Scientific from Neutral to Underweight and set a new price target of $4.00 from $40.00 previously

    11/20/24 9:49:17 AM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific downgraded by TD Cowen with a new price target

    TD Cowen downgraded Danimer Scientific from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    8/13/24 7:29:01 AM ET
    $DNMR
    Major Chemicals
    Industrials

    $DNMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Danimer Scientific Inc.

    SC 13G - Danimer Scientific, Inc. (0001779020) (Subject)

    11/14/24 3:28:09 PM ET
    $DNMR
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Danimer Scientific Inc.

    SC 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

    7/8/24 4:36:39 PM ET
    $DNMR
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by Danimer Scientific Inc. (Amendment)

    SC 13G/A - Danimer Scientific, Inc. (0001779020) (Subject)

    1/29/24 5:25:54 PM ET
    $DNMR
    Major Chemicals
    Industrials

    $DNMR
    Leadership Updates

    Live Leadership Updates

    View All

    Danimer Scientific Announces New Directors

    Dr. David Moody and Richard Altice to Join the Danimer Board Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading, next-generation bioplastics company focused on the production of biodegradable materials, is pleased to announce that Dr. David Moody and Mr. Richard Altice have been appointed as members of Danimer's Board of Directors. Dr. Moody's appointment is effective immediately, and Mr. Altice's appointment is effective as of April 15, 2024. Dr. David J. Moody currently is a member of the Board of Directors of Jadex Inc., a US-based manufacturing and material science company utilizing innovation and technology to develop sustainable products that serve the me

    1/18/24 4:30:00 PM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific Appoints Stephen Martin as Chief Legal Officer and Corporate Secretary

    Martin, a Duke University graduate and former Air Force officer, brings experience managing the legal affairs of publicly traded companies Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of biodegradable materials, today announced it has appointed Stephen Martin as Chief Legal Officer and Corporate Secretary. In this role, Martin will manage a wide range of legal matters across the company as Danimer continues to expand its manufacturing capacity to meet demand in the fast-growing bioplastics market. Martin joins Danimer from Kaman Distribution Group, a leading national distributor o

    9/20/22 8:30:00 AM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific Appoints Anthony Austin as Chief Human Resource Officer

    Austin brings more than 30 years of human resources leadership experience with PepsiCo, Delta Air Lines, Winn-Dixie and others Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next-generation bioplastics company focused on the development and production of biodegradable materials, today announced it has appointed Anthony Austin as Chief Human Resource Officer. In this role, Austin will focus on building best-in-class HR processes to strategically support the Company's growth as it continues to expand its manufacturing capacity. Austin joins Danimer from Bedrock Manufacturing Co., the parent company of Shinola, a luxury watch, leather and jewelry manufacturer an

    4/20/22 8:00:00 AM ET
    $DNMR
    Major Chemicals
    Industrials

    $DNMR
    Financials

    Live finance-specific insights

    View All

    Danimer Scientific Announces Common Stock Expected to Begin Trading Promptly on OTCQX Marketplace

    –Dividend warrants continue to trade on OTCQX marketplace under "DNMRW"– Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, today announced that it received notice the New York Stock Exchange ("NYSE") suspended trading of its common stock on the NYSE effective immediately and started the process to delist its common stock from the NYSE. The start of the delisting process follows the NYSE's determination under Rule 802.01B of the NYSE Listed Company Manual that the Company did not meet the continued listing standard that requires listed companies to maintain a

    12/31/24 8:00:00 AM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific Announces Third Quarter 2024 Results

    --Additional Resin Orders and Deliveries Continue to Support 20-Million Pound Cutlery Award –- -- 100% Compostable Skittles® Bag Made with Nodax® PHA Featured at NFL Game -- Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading next generation bioplastics company focused on the development and production of biodegradable materials, announced today financial results for its third quarter ended September 30, 2024. Richard N. Altice, Interim Chief Executive Officer of Danimer, commented, "We completed the third quarter in line with our expectations considering the temporary impact of Starbucks' reapportionment of their Nodax-based straw business between our convert

    11/19/24 8:30:00 AM ET
    $DNMR
    Major Chemicals
    Industrials

    Danimer Scientific Announces Release Date for Third Quarter 2024 Results

    Danimer Scientific, Inc. (NYSE:DNMR) ("Danimer" or the "Company"), a leading, next-generation bioplastics company focused on the development and production of biodegradable materials, announced today that the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 19, 2024. A webcast and conference call will be held that same day at 10:00 a.m. Eastern Time to review the Company's third quarter results. The webcast of the conference will be accessible on the Investor Relations section of the Company's website at https://ir.danimerscientific.com. For those unable to access the webcast, the conference call will be accessible domestically o

    11/14/24 9:00:00 AM ET
    $DNMR
    Major Chemicals
    Industrials